---
title: Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic
  Blasts
date: '2024-04-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38610966/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240413180704&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation
  of malignant precursor cells. Treatment consists of multiagent chemotherapy followed
  by allogeneic stem cell transplantation in high-risk patients. In addition, patients
  bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI)
  therapy. On the other hand, monoclonal antibody therapy is increasingly used in
  both clinical trials and real-world settings. The introduction of rituximab ...
disable_comments: true
---
B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy. On the other hand, monoclonal antibody therapy is increasingly used in both clinical trials and real-world settings. The introduction of rituximab ...